PAOG Adds Bioidentical Synthetic CBD To Research Pipeline

Sandusky, OH -- November 8, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced the company adding bioidentical synthetic CBD to its overall research initiative.

PAOG management highlights the fact that CBD extracted from hemp, as hemp legalization continues to evolve, has certainly brought the multitude of potential health benefits from CBD to light. PAOG has a number of both CBD pharmaceutical and nutraceutical developments under way. Now, PAOG will add bioidentical synthetic CBD to both its pharmaceutical and nutraceutical initiatives.

Many common over-the-counter supplements such as vitamin C and D are not organic compounds but otherwise synthetically produced in a lab. Even though they are not derived from natural resources such as fruit, they are nevertheless bioidentical to the natural compounds. Synthetic CBD can be produced the same way and the synthetic CBD has the potential of being more pure in regard to having less contaminants from the extraction process, and less presence of other and conflicting cannabinoids, in addition to being more consistent in structure (See “Natural Versus Synthetic CBD” to learn more)

PAOG continues to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

The company has been conducting an in-depth review of its current RespRx CBD pharmaceutical development project with its CRO partner, industry consultants and other pharmaceutical firms in an effort to explore various opportunities to accelerate and diversify development.

As part of the in-depth review, PAOG recently announced entertaining a partnership opportunity that could accelerate the ongoing development of its RespRx CBD.

As the in-depth review continues, PAOG has now identified derivate opportunities from its research to launch additional pharmaceutical product development projects. The identified opportunities PAOG plans to pursue have fast-track potential and are likely to result in a pharmaceutical product reaching market before RespRx.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group